Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 125 versus BICILLIN L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 125 versus BICILLIN L A.
AUGMENTIN '125' vs BICILLIN L-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
One AUGMENTIN '125' tablet (amoxicillin 125 mg, clavulanate 31.25 mg) orally every 8 hours for mild to moderate infections.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours (prolonged in renal impairment; up to 7-20 hours in anuria). Clavulanate: 0.9-1.2 hours (increased in renal impairment).
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~30-50% excreted unchanged in urine. Small amounts eliminated in bile and feces.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic